

Pursuant to the provisions of article 82 of the Spanish Securities Market Act (*Ley 24/1988, de 28 de julio, del Mercado de Valores*), Grifols, S.A. (“**Grifols**”) hereby notifies the National Securities Market Commission of the following

RELEVANT EVENT

On 28 March 2014, the Japanese Red Cross Society (JRC) signed a seven-year agreement to use Grifols' Procleix nucleic acid blood screening systems to screen the nation's blood supply (approximately 5.3 million donations each year) for viral diseases such as HIV and Hepatitis prior to their release for medical use. The total 7 year agreement value approaches \$375,000,000 (€274,000,000), at current exchange rates, in products and services to Grifols. Following Grifols' acquisition of the blood transfusion testing unit of Novartis in January 2014 (which did business as "Novartis Diagnostics"), the agreement has been executed through the legal entity of Novartis Pharma KK, which has been designated for this purpose as the Grifols distributor in Japan. Procleix products are jointly developed with long-standing NAT development partner Hologic (formerly Gen-Probe).

In Barcelona, 31 March 2014

Raimon Grifols Roura
Secretary to the Board of Directors